We are focused on delivering potentially transformational medicines to people living with obesity and diabetes.
The novel dual incretin modulators we are developing arose out of our proprietary technology platform called Chemotype Evolution. This platform enabled us to develop product candidates with the potential to produce significant weight loss and glycemic control.
Carmot’s founders had a vision of applying Chemotype Evolution to create breakthrough therapeutics and improve our mechanistic understanding of complex signaling pathways.